Author:
Pansiritanachot Wasin,Ruangsomboon Onlak,Limsuwat Chok,Chakorn Tipa
Abstract
Abstract
Background
There is limited evidence regarding factors associated with mortality in septic patients receiving etomidate. This study aimed to determine independent pre-intubation factors predicting 28-day mortality in septic patients receiving single-dose etomidate as an induction agent during rapid sequence intubation (RSI).
Methods
This single-center retrospective cohort study included intubated septic patients receiving etomidate as an induction agent during RSI in the emergency department of Siriraj hospital, Bangkok, Thailand, between January 1st, 2016 and June 30th, 2020. Pre-intubation characteristics were compared between survivors and non-survivors. Independent risk factors associated with 28-day mortality were identified using the Cox proportional hazards regression model. Association between etomidate dosage and mortality was also determined.
Results
A total of 344 patients, 238 (69%) survivors and 106 (31%) non-survivors, were included in the analyses. The initial Cox hazards model identified a pre-intubation lactate level ≥ 4 mmol/L as an independent factor associated with mortality (adjusted Hazards ratio [aHR] 2.66, 95% confidence interval [CI] 1.55–4.56). After removing lactate level from the model due to limited lactate values in the data, cancer was also predictive of 28-day mortality (aHR 1.83, 95%CI 1.10–3.04), while patients with respiratory infections and underlying chronic lung disease were associated with lower mortality (aHR 0.54, 95%CI 0.37–0.80 and aHR 0.57, 0.33–0.96, respectively). Etomidate dosage was not associated with mortality in our study.
Conclusion
In septic patients who received a single dose of etomidate, a pre-intubation lactate level ≥ 4 mmol/L and cancer were associated with increased 28-day mortality, while respiratory infection and underlying chronic lung disease were associated with lower mortality. Physicians may take these factors into consideration when selecting induction agents for septic patients.
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM. Tintinalli’s emergency medicine: a comprehensive study guide. 8th ed. New York: McGraw-Hill Education; 2016. p. 187–8.
2. Schwartz A, Brotfain E, Koyfman L, Klein M. Cardiac Arrhythmias in a Septic ICU population: a review. J Crit Care Med. 2015;1(4):140–6.
3. De Jong FH, Mallios C, Jansen C, Scheck PAE, Lamberts SWJ. Etomidate suppresses adrenocortical function by inhibition of 11β-hydroxylation. J Clin Endocrinol Metab. 1984;59(6):1143–7.
4. Lipiner-Friedman D, Sprung CL, Laterre PF, Weiss Y, Goodman SV, Vogeser M, et al. Adrenal function in sepsis: The retrospective Corticus cohort study. Crit Care Med. 2007;35(4):1012–8.
5. Albert SG, Ariyan S, Rather A. The effect of etomidate on adrenal function in critical illness: A systematic review. Intensive Care Med. 2011;37(6):901–10.